Grisnilimab Setaritox Biosimilar Antibody-Toxin Conjugate (CD7) for Research

Cat No.: GMP-Bios-INN-858

Pre-made Grisnilimab Setaritox benchmark antibody (Whole mAb ADC, anti-CD7 therapeutic antibody, Anti-GP40/LEU-9/TP41/Tp40 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-858-1mg 1mg
GMP-Bios-INN-858-10mg 10mg
GMP-Bios-INN-858-100mg 100mg
GMP-Bios-INN-858-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Grisnilimab Setaritox Biosimilar, Whole Mab Adc, Anti-Cd7 Antibody: Anti-GP40/LEU-9/TP41/Tp40 therapeutic antibody Drug Conjugate
INN Name Grisnilimab Setaritox
TargetCD7
FormatWhole mAb ADC
DerivationMus musculus
Species Reactivityhuman
CH1 IsotypeIgG2a - lambda
VD LCIgG2a - lambda
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesXenikos BV (Nijmegen Netherlands)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0



About target - CD7

1. Protein T-cell antigen CD7

2. Gene CD7

3. Organism Homo sapiens (Human)

Function
Not yet known.